PETER MORRIS: Open Payments
NPI 1275085649 · LAWRENCEVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,414 in 80 payments from 10 companies in 2025. Trend: 2023 $562 · 2024 $884 · 2025 $1,414
Food & beverage: $1,414
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 16 | $294 |
| Otsuka America Pharmaceutical, Inc. | 13 | $230 |
| Neurocrine BioSciences, Inc. | 12 | $213 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $180 |
| E.R. Squibb & Sons, L.L.C. | 10 | $178 |
| Alkermes, Inc. | 6 | $108 |
| Teva Pharmaceuticals USA, Inc. | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| ABBVIE INC. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: INVEGA SUSTENNA, INGREZZA, CAPLYTA, COBENFY, REXULTI, ARISTADA, ABILIFY MAINTENA, UZEDY.
Industry payments across NJ — which companies pay providers there.
